EP3896062A4 - Isoindolinverbindung, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung der isoindolinverbindung - Google Patents

Isoindolinverbindung, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung der isoindolinverbindung Download PDF

Info

Publication number
EP3896062A4
EP3896062A4 EP19893951.4A EP19893951A EP3896062A4 EP 3896062 A4 EP3896062 A4 EP 3896062A4 EP 19893951 A EP19893951 A EP 19893951A EP 3896062 A4 EP3896062 A4 EP 3896062A4
Authority
EP
European Patent Office
Prior art keywords
isoindoline compound
preparation
application
pharmaceutical composition
isoindoline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19893951.4A
Other languages
English (en)
French (fr)
Other versions
EP3896062A1 (de
Inventor
Xiaohua Chen
Jia Li
Yu Cheng
Yubo ZHOU
Huijun NIE
Yujie Wang
Andi GUO
Weijuan KAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Original Assignee
Shanghai Institute of Materia Medica of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS filed Critical Shanghai Institute of Materia Medica of CAS
Publication of EP3896062A1 publication Critical patent/EP3896062A1/de
Publication of EP3896062A4 publication Critical patent/EP3896062A4/de
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP19893951.4A 2018-12-06 2019-12-06 Isoindolinverbindung, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung der isoindolinverbindung Pending EP3896062A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811488140 2018-12-06
PCT/CN2019/123643 WO2020114482A1 (zh) 2018-12-06 2019-12-06 一类异吲哚啉类化合物、其制备方法、药物组合物及其应用

Publications (2)

Publication Number Publication Date
EP3896062A1 EP3896062A1 (de) 2021-10-20
EP3896062A4 true EP3896062A4 (de) 2022-06-15

Family

ID=70973433

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19893951.4A Pending EP3896062A4 (de) 2018-12-06 2019-12-06 Isoindolinverbindung, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung der isoindolinverbindung

Country Status (6)

Country Link
US (1) US20220041578A1 (de)
EP (1) EP3896062A4 (de)
CN (1) CN111285850B (de)
AU (1) AU2019392231B2 (de)
CA (1) CA3122317C (de)
WO (1) WO2020114482A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112745298B (zh) * 2019-10-30 2024-04-09 中国科学院上海药物研究所 多取代异吲哚啉类化合物、其制备方法、药物组合物及用途
CA3177252A1 (en) * 2020-04-30 2021-11-04 Xiaobao Yang Heterocycle and glutarimide skeleton-based compounds and applications thereof
CN114456173B (zh) * 2020-11-10 2023-09-19 江苏恒瑞医药股份有限公司 稠环基取代的环己二酰亚胺类衍生物、其制备方法及其在医药上的应用
WO2022148358A1 (zh) * 2021-01-05 2022-07-14 江苏恒瑞医药股份有限公司 稠杂环基取代的环己二酰亚胺衍生物、其制备方法及其在医药上的应用
WO2022152821A1 (en) 2021-01-13 2022-07-21 Monte Rosa Therapeutics Ag Isoindolinone compounds
CN114805357B (zh) * 2021-01-21 2023-12-19 四川大学 一种靶向setdb1-ttd的小分子抑制剂及其制药用途
CN115246783A (zh) * 2021-04-26 2022-10-28 中国科学院上海药物研究所 1,3-环己二酮类化合物及其药物组合物和应用
CN117186061A (zh) * 2022-06-07 2023-12-08 天津谷堆生物医药科技有限公司 4-羰基氨基异吲哚啉-1-酮衍生物、包括其的组合物及使用方法
CN117186062A (zh) * 2022-06-07 2023-12-08 天津谷堆生物医药科技有限公司 4-羰基氨基异吲哚啉-1,3-二酮类化合物及其制备方法、药物组合及用途
WO2023246944A1 (zh) * 2022-06-24 2023-12-28 中国科学院上海药物研究所 一类取代的4-氨基异吲哚啉类化合物、其制备方法、药物组合物及应用
WO2024051766A1 (zh) * 2022-09-08 2024-03-14 标新生物医药科技(上海)有限公司 基于cereblon蛋白设计的分子胶化合物及其应用
US20240158370A1 (en) * 2022-09-09 2024-05-16 Innovo Therapeutics, Inc. CK1 alpha AND DUAL CK1 alpha / GSPT1 DEGRADING COMPOUNDS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
JP5578785B2 (ja) 2005-08-31 2014-08-27 セルジーン コーポレイション イソインドール−イミド化合物及びそれを含有する組成物及びそれの使用法
CL2007002513A1 (es) 2006-08-30 2008-04-04 Celgene Corp Soc Organizada Ba Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
US8877780B2 (en) 2006-08-30 2014-11-04 Celgene Corporation 5-substituted isoindoline compounds
KR20170093996A (ko) 2007-03-20 2017-08-16 셀진 코포레이션 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
BRPI0919942B1 (pt) 2008-10-29 2019-02-19 Celgene Corporation Composto, composição farmacêutica que o compreende e uso do referido composto
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
ME03441B (de) 2010-02-11 2020-01-20 Celgene Corp Arylmethoxyisoindolinderivate, zusammensetzungen damit und verfahren zur verwendung davon
PL3214081T3 (pl) 2014-10-30 2021-04-06 Kangpu Biopharmaceuticals, Ltd. Pochodna izoindoliny, półprodukt, sposób wytwarzania, kompozycja farmaceutyczna i ich zastosowanie
US10759808B2 (en) * 2016-04-06 2020-09-01 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
EP3455219A4 (de) * 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Amingebundene c3-glutarimiddegronimere für zielproteinabbau
CA3025806C (en) * 2016-06-23 2023-04-04 Dana-Farber Cancer Institute, Inc. Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
MX2019007649A (es) * 2016-12-23 2019-09-10 Arvinas Operations Inc Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente.
JP2021519337A (ja) * 2018-03-26 2021-08-10 シー４ セラピューティクス， インコーポレイテッド Ｉｋａｒｏｓの分解のためのセレブロン結合剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number Publication date
CA3122317A1 (en) 2020-06-11
CN111285850B (zh) 2022-04-22
EP3896062A1 (de) 2021-10-20
WO2020114482A1 (zh) 2020-06-11
AU2019392231B2 (en) 2022-10-20
CA3122317C (en) 2023-10-03
CN111285850A (zh) 2020-06-16
US20220041578A1 (en) 2022-02-10
AU2019392231A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
EP3896062A4 (de) Isoindolinverbindung, verfahren zu ihrer herstellung, pharmazeutische zusammensetzung und verwendung der isoindolinverbindung
EP3875458A4 (de) Diphenylähnliche verbindungen, zwischenprodukte davon, herstellungsverfahren dafür, pharmazeutische zusammensetzung davon und verwendungen davon
EP3862348A4 (de) Isoindolinverbindung, herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon
EP3835296A4 (de) Ketoamidverbindung und herstellungsverfahren, pharmazeutische zusammensetzung und verwendung davon
EP3753941A4 (de) Pyrimidinkondensierte cyclische verbindung, verfahren zu ihrer herstellung und verwendung davon
EP3539960A4 (de) Stickstoffhaltige makrocyclische verbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung daraus und anwendung davon
EP3590924A4 (de) Neuartiges isoindolinderivat sowie pharmazeutische zusammensetzung und anwendung davon
EP3279207A4 (de) Neuartige verbindung von 4'-thionukleosid sowie herstellungsverfahren dafür, pharmazeutische zusammensetzung davon und anwendung davon
EP3868399A4 (de) Immunzusammensetzung, herstellungsverfahren dafür und anwendung davon
EP3626718A4 (de) Fünf- und sechsgliedrige aza-aromatische verbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung und anwendung
EP3580208A4 (de) Neuartige heterocyclische verbindung, deren herstellungsverfahren und pharmazeutische zusammensetzung damit
EP3825322C0 (de) Polypeptidverbindung, pharmazeutische zusammensetzung, verfahren zu ihrer herstellung und verwendung davon
EP3825308A4 (de) Verbindung, zusammensetzung und ihre verwendung zur herstellung eines arzneimittels
EP3670511A4 (de) Tetrahydroprotoberberinverbindung, verfahren zu ihrer herstellung und ihre verwendung sowie pharmazeutische zusammensetzung
EP3647313A4 (de) Substituierte aryletherverbindung, herstellungsverfahren dafür, pharmazeutische zusammensetzung und verwendung davon
EP3406602A4 (de) 1-sulfonamido-4-aryloxyverbindung und herstellungsverfahren und medizinische anwendung davon
EP3744316A4 (de) Ophthalmische pharmazeutische zusammensetzung, herstellungsverfahren dafür und anwendung davon
EP3858833A4 (de) Aminonordekanderivat und herstellungsverfahren dafür und anwendung davon
EP3838265A4 (de) Injizierbare pharmazeutische zusammensetzung und herstellungsverfahren dafür
EP3842426A4 (de) Herstellungsverfahren von pyrrolo-amino-pyridazinon-verbindungen und zwischenprodukt davon
EP3447054A4 (de) Verbindung und herstellungsverfahren dafür, zusammensetzung und anwendung davon
EP3808751A4 (de) Camptothecinderivat, herstellungsverfahren dafür und anwendung davon
EP3785713A4 (de) Salz von cetagliptin, herstellungsverfahren dafür, pharmazeutische zusammensetzung und verwendung davon
EP4056551A4 (de) Kristallform i eines curcumin-derivats, herstellungsverfahren dafür und verwendung davon
EP3929198A4 (de) Heterocyclische verbindung, pharmazeutische zusammensetzung damit, verfahren zu ihrer herstellung und ihre verwendung

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210705

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40053022

Country of ref document: HK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220513

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20220509BHEP

Ipc: A61K 31/4745 20060101ALI20220509BHEP

Ipc: A61K 31/4412 20060101ALI20220509BHEP

Ipc: C07D 401/14 20060101ALI20220509BHEP

Ipc: C07D 401/04 20060101AFI20220509BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231106